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The mechanisms by which alcohol causes cell injury are not clear. A major mechanism is the role of lipid peroxidation and
oxidative stress in alcohol toxicity. Many pathways have been suggested to play a role in how alcohol induces oxidative stress.
Considerable attention has been given to alcohol elevated production of lipopolysaccharide (LPS) and TNFα and to alcohol
induction of CYP2E1. These two pathways are not exclusive of each other; however, interactions between them, have not been
extensively evaluated. Increased oxidative stress from induction of CYP2E1 sensitizes hepatocytes to LPS and TNFα toxicity
and oxidants, activation of inducible nitric oxide synthase and p38 and JNK MAP kinases, and mitochondrial dysfunction
are downstream mediators of this CYP2E1-LPS/TNFα-potentiated hepatotoxicity. This paper will summarize studies showing
potentiated interactionsbetween thesetworiskfactorsinpromotingliverinjuryandthemechanismsinvolvedincludingactivation
of the mitogen-activated kinase kinase kinase ASK-1. Decreasing either cytosolic or mitochondrial thioredoxin in HepG2 cells
expressing CYP2E1 causes loss of cell viability and elevated oxidative stress via an ASK-1/JNK-dependent mechanism. We
hypothesize that similar interactions occur as a result of ethanol induction of CYP2E1 and TNFα.
1.Introduction
Theabilityofacuteandchronicethanoltreatmenttoincrease
production of reactive oxygen species and enhance peroxi-
dation of lipids, protein, and DNA has been demonstrated
in a variety of systems, cells, and species, including humans
[1]. Despite a tremendous growth in understanding alcohol
metabolism and actions, the mechanism(s) by which alcohol
causes cell injury are still not clear. A variety of leading
mechanisms have been brieﬂy summarized [2–4], and it is
likely that many of them ultimately converge as they reﬂect
a spectrum of the organism’s response to the myriad of
direct and indirect actions of alcohol. A major mechanism
that is a focus of considerable research is the role of lipid
peroxidation and oxidative stress in alcohol toxicity. Under
certainconditions,suchasacuteorchronicalcoholexposure,
production of reactive oxygen species (ROS) is enhanced
and/or the level or activity of antioxidants is reduced. The
resulting state, which is characterized by a disturbance in the
balance between ROS production, on one hand, and ROS
removal and repair of damaged complex molecules, on the
other is called oxidative stress.
ROS have been implicated in many of the major diseases
that plague mankind, including the toxicity of O2 itself;
hyperbaric O2; ischemia-reperfusion injury; cardiovascu-
lar diseases; atherosclerosis; carcinogenesis; diabetes; neu-
rodegenerative diseases, including Parkinson’s disease and
Alzheimer’s disease; toxicity of heavy metals, for example,
iron; asbestos injury; radiation injury; vitamin deﬁciency;
drug (e.g., redox cycling agents) toxicity; aging; inﬂamma-
tion; smoke toxicity; emphysema; toxicity of acute and
chronic ethanol treatment [2–6]. ROS can be produced
from many systems in cells including the mitochondrial
respiratory chain [7], the cytochrome P450s [8, 9], oxida-
tive enzymes such as xanthine oxidase, aldehyde oxidase,2 International Journal of Hepatology
cyclooxygenase, monoamine oxidase, and the NADPH oxi-
dase complex [10], autooxidation of heme proteins such
as ferrohemoglobin or myoglobin, or biochemicals such as
catecholamines, quinones, or tetrahydrobiopterins. In ad-
dition to these cellular sources of ROS, environmental sour-
ces of ROS include radiation, UV light, smoke, and certain
drugs which are metabolized to radical intermediates or
which can redox cycle. ROS are toxic to cells because they
can react with most cellular macromolecules inactiving en-
zymes or denaturing proteins, causing DNA damage such
as strand breaks, base removal, or base modiﬁcations which
can result in mutation, peroxidation of lipids which can re-
sult in destruction of biological membranes and produce re-
active aldehydic products such as malondialdehyde or 4-hy-
droxynonenal. A variety of enzymatic and non-enzymatic
mechanisms have evolved to protect cells against ROS, in-
cluding the superoxide dismutases, which remove O2
−; cata-
lase and the glutathione (GSH) peroxidase system which re-
move H2O2; glutathione transferases which can remove re-
active intermediates and lipid aldehydes, metallothioneins,
heme oxygenase, thioredoxin which remove various ROS;
ceruloplasmin and ferritin which help remove metals such as
iron which promote oxidative reactions; nonenzymatic, low-
molecular-weight antioxidants such as GSH itself, vitamin
E, ascorbate (vitamin C), vitamin A, ubiquinone, uric acid,
and bilirubin [11, 12]. Oxidative stress or toxicity by ROS
reﬂects a balance between the rates of production of ROS
compared to the rates of removal of ROS plus repair of dam-
aged cellular macromolecules. While excess ROS can cause
toxicity, macrophages and neutrophils contain an NADPH
oxidase which produces ROS to destroy foreign organisms
[13], and the enzyme myeloperoxidase catalyzes a reaction
between H2O2 and chloride to produce the powerful oxidant
hypochlorite (bleach) to help destroy foreign invaders. In
addition, ROS at low concentrations, especially H2O2,m a y
be important in signal transduction mechanisms in cells and
thus be involved in cellular physiology and metabolism [14].
Many pathways have been suggested to play a key role in
how ethanol induces “oxidative stress” [1–4]. Some of these
include redox state changes (decrease in the NAD+/NADH
redox ratio) produced as a result of ethanol oxidation by
alcohol and aldehyde dehydrogenases; production of the
reactive product acetaldehyde as a consequence of ethanol
oxidation by all major oxidative pathways; damage to mito-
chondria which results in decreased ATP production; direct
or membrane eﬀects caused by hydrophobic ethanol inter-
action with either phospholipids or protein components or
enzymes; ethanol-induced hypoxia, especially in the peri-
c e n t r a lz o n eo ft h el i v e ra c i n u sa so x y g e ni sc o n s u m e di n
order for the liver to detoxify ethanol via oxidation; etha-
nol eﬀects on the immune system and altered cytokine pro-
duction;ethanol-induced increase in bacterial-derivedendo-
toxin with subsequent activation of Kupﬀer cells; ethanol
induction of CYP2E1; ethanol mobilization of iron which
results in enhanced levelsof low-molecular-weight nonheme
iron; eﬀects on antioxidant enzymes and chemicals, particu-
larly mitochondrial and cytosolic glutathione; one electron
oxidation of ethanol to the 1-hydroxy ethyl radical; con-
version of xanthine dehydrogenase to the xanthine oxidase
f o r m .A g a i n ,m a n yo ft h e s ep a t h w a y sa r en o te x c l u s i v eo fo n e
another, and it is likely that several, indeed many, systems
c o n t r i b u t et ot h ea b i l i t yo fe t h a n o lt oi n d u c eas t a t eo fo x i -
dative stress.
2.KupfferCellsand AlcoholicLiverDisease
Kupﬀer cells are stimulated by chronic ethanol treatment
to produce free radicals and cytokines, including TNFα,
which plays a role in ALD [15, 16]. This stimulation
is mediated by bacterial-derived endotoxin, and ALD is
decreased when gram-negative bacteria are depleted from
the gut by treatment with lactobacillus or antibiotics [17].
The TNFα receptor superfamily consists of several members
sharing a sequence homology, the death domain, located
in the intracellular portion of the receptor. These “death”
receptors, including Fas, TNF-R1, and TRAIL-R1/TRAIL-
R2, are expressed in hepatocytes and when stimulated by
their respective ligands, FasL, TNFα,o rT R A I L ,h e p a t o -
cyte injury can occur [18]. Lipopolysaccharide (LPS) is
a component of the outer wall of gram-negative bacteria
that normally inhabit the gut. LPS penetrates the gut
epithelium only in trace amounts; however, LPS absorption
can be elevated under pathophysiological conditions such as
alcoholicliverdisease [19]. WhenLPSis released from gram-
negativebacteriaandentersthebloodstream,thelivertightly
regulates the entry and processing of LPS by virtue of its
ability to clear LPS and respond to LPS [20]. In addition
to its ability to clear LPS, the liver also responds to LPS
and produces cytokines. LPS directly causes liver injury by
mechanisms involving inﬂammatory cells such as Kupﬀer
cells, and chemical mediators such as superoxide, nitric
oxide,andtumornecrosisfactor(TNFα)andothercytokines
[21–23]. In addition, LPS potentiates liver damage induced
by hepatotoxins including ethanol [24–29]. In experimental
alcoholic liver disease, the combination of LPS and chronic
ethanol produce hepatic necrosis and inﬂammation [27–
29]. Ethanol alters gut microﬂora, the source of LPS,
and ethanol increases the permeability of the gut, thus
increasingthedistributionofLPSfromthegutintotheportal
circulation (endotoxemia). This causes activation of Kupﬀer
cells, the resident macrophages in liver, resulting in release of
chemical mediators including cytokines and reactive oxygen
species (ROS), and subsequently, alcoholic liver disease
[30]. Destruction of Kupﬀer cells with gadolinium chloride
attenuated ALD [15]. A major advance was the ﬁnding that
anti-TNFα antibodies protect against ALD [16]. NADPH
oxidase was identiﬁed as a key enzyme for generating ROS
in Kupﬀer cells after ethanol treatment [31]. Moreover, in
mice deﬁcient in a subunit of NADPHoxidase, p47phox, the
ethanol-induced increase in ROS and TNFα and liver injury
was decreased [32]. The role of TNFα in ALD was further
validated by the ﬁndings that the ethanol-induced pathology
was nearly blocked in TNFα receptor1 knockout mice [33].
The transcription factor nuclear factor-kappaB (NF-κB)
in Kupﬀer cells regulates activation of many inﬂammatory
genes, including TNFα.E n d o t o x i na c t i v a t e sN F - κB, leading
to the hypothesis that inhibition of NF-κBi nK u p ﬀer cells
would prevent ALD [34]. Administration of an adenovirusInternational Journal of Hepatology 3
encoding for the IkB superrepressor to rats chronically
infused with ethanol blunted the ethanol-induced activation
of NF-κB, TNFα production, and pathological changes. A
generalschemetoexplaintheseresultsisthatchronicethanol
treatment elevates endotoxin levels, endotoxin activates
Kupﬀercellstoproducefree radicalsviaNADPHoxidase,the
freeradicalsactivateNF-κB,leadingtoanincreaseinproduc-
tion of TNFα, followed eventually by tissue damage [29].
3.CYP2E1
CYP2E1 metabolizes a variety of small, hydrophobic sub-
strates including solvents such as chloroform and carbon
tetrachloride, aromatic hydrocarbons such as benzene and
toluene, alcohols such as ethanol and pentanol, aldehy-
des such as acetaldehyde, halogenated anesthetics such
as enﬂurane and halothane, nitrosamines such as N,N-
dimethylnitrosamine, and drugs such as chlorzoxazone and
acetaminophen [35–41]. From a toxicological point of
view, interest in CYP2E1 revolves around the ability of
this P450 to metabolize and activate many toxicologically
important compoundssuchasethanol,carbontetrachloride,
acetaminophen, benzene, halothane, and many other halo-
genated substrates. Procarcinogens including nitrosamines
and azo compounds are eﬀective substrates for CYP2E1.
Toxicitybytheabovecompoundsisenhancedafterinduction
of CYP2E1, for example, by ethanol treatment, and toxicity
is reduced by inhibitors of CYP2E1 or in CYP2E1 knockout
mice [42].
Molecular oxygen itself is likely to be the most important
substrate for CYP2E1 [8, 9] .C Y P 2 E 1 ,r e l a t i v et os e v e r a l
other P450 enzymes, displays high NADPH oxidase activity
as it appears to be poorly coupled with NADPH-cytochrome
P450 reductase [43, 44]. CYP2E1 was the most eﬃcient
P450 enzyme in the initiation of NADPH-dependent lipid
peroxidation in reconstituted membranes among ﬁve dif-
ferent P450 forms investigated. Furthermore, anti-CYP2E1
IgG inhibited microsomal NADPH oxidase activity and
microsomal lipid peroxidation dependent on P450, but
not lipid peroxidation initiated by the action of NADPH-
cytochrome P450 reductase [43].Inourlaboratory,wefound
that microsomes isolated from rats fed ethanol chronically
were about twofold to threefold more reactive in generating
superoxide radical and H2O2, and in the presence of ferric
complexes, in generating hydroxyl radical and undergoing
lipid peroxidation [45–48]. CYP2E1 levels were elevated
about threefold to ﬁvefold in liver microsomes after feeding
rats the Lieber-DeCarli diet for four weeks. In all the above
systems, the enhanced eﬀectiveness of microsomes isolated
from the ethanol-fed rats was prevented by addition of
chemical inhibitors of CYP2E1 and by polyclonal antibody
raised against CYP2E1 puriﬁed from pyrazole-treated rats,
conﬁrming that the increased activity in these microsomes
was due to CYP2E1.
Since CYP2E1 can generate ROS during its catalytic
cycle, and its levels are elevated by chronic treatment with
ethanol, CYP2E1 has been suggested as a major contributor
to ethanol-induced oxidative stress, and to ethanol-induced
liver injury [49–53]. Experimentally, a decrease in CYP2E1
induction was found to be associated with a reduction in
alcohol-induced liver injury [54–58]. A CYP2E1 transgenic
mouse model was developed that overexpressed CYP2E1.
When treated with ethanol, the CYP2E1 overexpressing
mice displayed higher transaminase levels and histological
features of liver injury compared with the control mice [59].
We developed an adenoviral vector which expresses hu-
man CYP2E1 and showed that infection of HepG2 cells with
this adenovirus potentiated acetaminophen toxicity as com-
pared to HepG2 cells infected with a LacZ expressing ade-
novirus [60]. Administration of the CYP2E1 adenovirus in
vivo to mice elevated CYP2E1 levels and activity and pro-
duced signiﬁcant liver injury compared to the LacZ-infected
mice as reﬂected by histopathology and elevated transam-
inase levels [61]. However, other studies suggested that
CYP2E1 may not play a role in alcohol liver injury based
upon studieswith gadolinium chloride or CYP2E1 knockout
mice [62, 63]. Bradford et al. [64]u s i n gC Y P 2 E 1a n d
NADPH oxidase knockout mice concluded that CYP2E1
was required for ethanol induction of oxidative stress to
DNA, whereas NADPH oxidase was required for ethanol-in-
duced liver injury. As mentioned earlier, it is likely that
several mechanisms contribute to alcohol-induced liver
injury and that ethanol-induced oxidative stress is likely to
arise from severalsources, includingCYP2E1, mitochondria,
and activated Kupﬀer cells.
4.LPS/TNFα-CYP2E1Interactions
As discussed above, abnormal cytokine metabolism is a
major feature of alcoholic liver disease. Rats chronically fed
ethanol were more sensitive to the hepatotoxic eﬀects of
administration of LPS and had higher plasma levels of TNFα
than control rats [65, 66]. Inthe intragastric model ofchron-
ic ethanol administration, the development of liver injury
coincided with an increase in TNFα, associated with an
increase in serum LPS [29]. Anti-TNFα antibody prevented
alcohol liver injury in rats [16], and mice lacking the TNFR1
receptor did not develop alcohol liver injury [33]. Taken as
a whole, these and other studies clearly implicate TNFα as
a major risk factor for the development of alcoholic liver
injury. One complication in this central role for TNFα is that
hepatocytes are normally resistant to TNFα-induced toxicity.
This led to the hypothesis that besides elevating TNFα, alco-
hol somehow sensitizes or primes the liver to become
susceptible to TNFα [67, 68]. Known factors which sensitize
the liver to TNFα are inhibitors of mRNA or protein
synthesis, which likely prevent the synthesis of protective
factors, inhibition of NF-κB activation in hepatocytes to
lower synthesis of such protective factors, depletion of
GSH, especially mitochondrial GSH, lowering of S-adenosyl
methionine (SAM) coupled to elevation of S-adenosyl hom-
ocysteine (SAH), that is, a decline in the SAM/SAH ratio,
or inhibition of the proteasome. Combined treatment with
ethanol plus TNFα is more toxic to hepatocytes and HepG2
E47 cells which express high levels of CYP2E1 than control
hepatocytes with lower levels of CYP2E1 or HepG2 C34
cells which do not express CYP2E1 [69]. RALA hepatocytes
with increased expression of CYP2E1 were sensitized to4 International Journal of Hepatology
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Figure 1: Eﬀect of pyrazole or LPS or LPS plus pyrazole on serum ALT (a) or AST (b) or liver histopathology (c). In (c), panels refer to (A)
saline; (B) pyrazole-treated; (C) LPS-treated; (D) LPS plus pyrazole treated. Arrows show necrotic foci with inﬂammatory cell inﬁltration.
Note: combined treatment with pyrazole plus TNFα produces liver injury. The CYP2E1 inhibitor, chlormethiazole (CMZ), protects against
LPSpluspyrazoletoxicityinmice.(d)ALT/ASTlevels.Sal:Saline-treated; P+L:pyrazoleplusLPStreated: C+P+L,CMZpluspyrazoleplus
LPS treated. (e) histopathology (top panels); 3-nitrotyrosine protein adducts (middle panels); 4-hydroxynonenal adducts (bottom panels).
In all panels, panel (a) is the saline treated; panel (b) is the LPS plus pyrazole treated; panel (c) refers to the CMZ plus LPS plus pyrazole
treated.
TNFα-mediated cell death [70]. These results suggest that
increased oxidative stress from CYP2E1 may sensitize isolat-
ed hepatocytes to TNFα-induced toxicity.
Either LPS or CYP2E1 is considered independent risk
factors involved in alcoholic liver disease, but mutual rela-
tionships or interactions between them are unknown. We
initiated studies to evaluate whether CYP2E1 contributes
or potentiates LPS- or TNFα-mediated liver injury in vivo.
These studies may provide an experimental model to better
understand mechanisms of ethanol-induced liver damage.
5.Pyrazole PotentiatesLPSToxicity[71,72]
Male, Sprague-Dawley rats (160–180g) were injected intra-
peritoneally with pyrazole (PY), 200mg per kg body wt,
once a day for 2 days to induce CYP2E1. After an overnight
fast, either saline or LPS (Sigma, serotype 055: BS, 10mg/kg
body wt) was injected via the tail vein. Rats were killed 8–
10hr after the LPS or saline injection and blood and liver
tissue collected. Neither pyrazole alone or LPS alone caused
liver injury as reﬂected by transaminase (ALT, AST) levels
or liver histopathology (Figures 1(a) and 1(b)). However,
the combination of LPS plus pyrazole increased AST and
ALT levels about fourfold over the levels in the pyrazole
alone orLPSalone groups(Figures1(a)and 1(b)).LPS-plus-
pyrazole-treatment induced extensive necrosis of hepato-
cytes,mainlylocatedbothinperiportalandpericentralzones
of the liver, accompanied by strong inﬁltration of inﬂam-
matory cells (Figure 1(c)). LPS alone treatment caused some
apoptosis and activation of caspases 3 and 9, whereas pyra-
zole treatment alone had no eﬀect. LPS plus pyrazole
treatment was not any more eﬀective than LPS alone in in-
creasing apoptosis, unlike the increases in necrosis and in-
ﬂammation.International Journal of Hepatology 5
To assess whether oxidative stress occurs after the various
treatments, malondialdehyde (MDA) levels as a reﬂection
of lipid peroxidation were assayed. Whereas pyrazole alone
or LPS alone did not elevate MDA levels over those found
with saline controls, the combination of LPS plus pyrazole
increased MDA levels about 65% (P<0.05 compared to
the other 3 groups). Protein carbonyl formation as a marker
for oxidized protein formation was determined. Low levels
of protein carbonyls were found in saline control livers.
Treatment with either LPS alone or pyrazole alone elevated
proteincarbonyl levels;however,striking increases inprotein
carbonyls were found in the combined LPS plus pyrazole
group. In situ detection of superoxide was measured using
the oxidation-dependent ﬂuorescent dye dihydroethidium.
Red ﬂuorescence was weak in saline control livers, was
slightlyincreased in eithertheLPS orpyrazole livers, andwas
highest in the LPS plus pyrazole livers. 3-Nitrotyrosine (3-
NT) protein adducts were detected by a slot blot technique.
3-NT adducts were highest in livers from the LPS-plus-
pyrazole-treated mice. Thus, several parameters of oxida-
tive/nitrosative stress were elevated in livers from the LPS
plus pyrazole-treated mice.
CYP2E1 catalytic activity (oxidation of P-nitrophenol to
p-nitrocatechol) was increased about 2-fold by either the
pyrazole alone or the pyrazole plus LPS treatments. LPS
alone slightly but not signiﬁcantly decreased CYP2E1 activi-
ty .LevelsofCYP2E1protein,measuredbyimmunoblotanal-
ysis, showed similar trends, being increased about 2-fold by
pyrazole or pyrazole plusLPS treatments. These results show
that pyrazole treatment enhanced LPS-induced necrosis,
not apoptosis. This enhanced liver injury is associated with
elevatedlevelsofCYP2E1 andincreased oxidative/nitrosative
stress generated by the combination of LPS plus elevated
CYP2E1.
To validate the role of CYP2E1 in the potentiation of
LPS toxicity by pyrazole, experiments with chlormethiazole
(CMZ) an inhibitor of CYP2E1 and with CYP2E1 knockout
mice were carried out [71]. C57BL/6 mice were injected
intraperitoneally with pyrazole, 150mg/kg body wt once a
day for 2 days or 0.9% saline. After an overnight fast, LPS,
4mg/kg body wt, or saline was injected IP. CMZ was inject-
ed in some mice at a concentration of 50mg/kg body wt
15 hours before and 30 minutes after the LPS treatment.
Mice were killed 3, 8, or 24h after LPS or saline injection. In
other experiments, CYP2E1 knockout mice, kindly provided
by Dr. Frank Gonzalez, NCI, NIH, and their genetic back-
ground SV129 controls were treated with pyrazole and LPS
as above. Initial experiments showed that neither pyra-
zole alone nor LPS alone produced liver injury under those
conditions. However, the LPS-plus-pyrazole-treatment pro-
duced signiﬁcant liver injury in mice, as was previously
shown in rats. Little injury occurred at 3 or 8hr after
the LPS administration, but did occur at 24h. The injury
in the LPS-plus-pyrazole-treated mice was associated with
an elevation in oxidative/nitrosative stress as reﬂected by
increases in 3-NT and 4-hydroxynonenal (HNE) protein ad-
ducts. Administration of CMZ to the LPS-plus-pyrazole-
treated mice decreased the elevated ALT and AST levels by
about 55 and 65%, respectively, (Figure 1(d)). Pathological
evaluation showed large necrotic areas in the livers from
the LPS-plus-pyrazole-treated-mice, but only small necrotic
foci were observed after treatment with CMZ (Figure 1(e)).
The treatment with CMZ also lowered the elevated oxida-
tive/nitrosative stress produced by the LPS plus pyrazole
treatment as only weak signals for formation of 4-HNE
adducts and 3-NT adducts were found after the CMZ treat-
ment (Figure 1(e)). The pyrazole plus LPS treatment pro-
duced a 2-fold increase in CYP2E1 catalytic activity, which
w a sp r e v e n t e da f t e rt h ea d m i n i s t r a t i o no fC M Z .T h u s ,C M Z
blocked the elevation of CYP2E1 in the LPS-plus-pyrazole-
treated mice, and this was associated with a decline in
oxidative/nitrosative stress and blunting of liver injury.
To further evaluate a role for CYP2E1 in the LPS plus
pyrazole toxicity, CYP2E1 knockout or wild-type con-
trol SV129 mice were treated with LPS plus pyrazole. As
with C57Bl/6 mice, liver injury was observed in the wild-
type SV129 mice treated with LPS plus pyrazole, but not
mice treated with LPS alone or pyrazole alone. Serum ALT
and AST levels were about 50% lower in LPS-plus-pyra-
zole-treated CYP2E1 knockout mice as compared to wild-
type mice. Pathological evaluation showed large necrotic
areas and widespread necrotic foci in wild-type mice, where-
as almost normal histology was found in the LPS-plus-
pyrazole-treated CYP2E1 knockout mice. Positive TUNEL
staining was also signiﬁcantly lower in the CYP2E1 null
mice compared to wild-type mice. Immunoblots conﬁrmed
the absence of CYP2E1 protein in the knockout mice, while
strong signals from CYP2E1 were detected in immunoblots
o ft h ew i l dt y p em i c e .T h u s ,i nb o t hr a t sa n dm i c e ,
the CYP2E1 inducer pyrazole potentiates LPS-induced
liver injury. This potentiation is associated with elevated
oxidative/nitrosative stress and is blocked by the CYP2E1
inhibitor CMZ and blunted in CYP2E1 knockout mice. We
hypothesize that CYP2E1-mediated oxidative stress may
synergize with LPS-generated oxidative stress in this model
to produce liver injury.
6.Pyrazole PotentiatesTNFα Toxicity [73, 74].
Since TNFα levels are elevated after LPS administration and
TNFα plays an important role in the eﬀects of LPS, we
determined if pyrazole treatment to induce CYP2E1 po-
tentiates TNFα toxicity as it did with LPS toxicity. Basically,
the same approaches described above were used, with injec-
tion of TNFα (50ug/kg body wt.) replacing the LPS treat-
ment.
Figure 2(a) shows that ALT and AST levels were low in
the saline control mice and in the pyrazole-treated mice
challenged with saline. Treatment of controlmice with TNFα
elevated transaminase levels by about 2-3-fold. Treatment of
the pyrazole mice with TNFα elevated transaminase levels
more than 3-fold over the TNFα-saline control treated mice.
Liver sections were stained with H&E for morphological
evaluation. The saline and TNFα treated mice showed
normal liver morphology. Liver from pyrazole treated
mice showed some vacuolar degeneration. Liver from the
TNFα-plus-pyrazole-treated mice showed several necrotic
loci (arrows), and typical pathology morphology changes6 International Journal of Hepatology
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Figure 2: Pyrazole potentiates TNFα hepatotoxicity and oxidative stress in mice. Mice were treated with either saline or pyrazole alone or
TNFα alone or pyrazole plus TNFα followed by assays for (a) serum ALT/AST, (b) histopathology (arrows show necrotic zones), (c) lipid
peroxidationasreﬂected bylevelsofTBARs inlivercell lysatesandinisolatedmitochondrialfractions.Note:combinedtreatment withTNFα
plus pyrazole produces liver injury. (d) Serum ALT and AST levels in pyrazole plus TNFα-treated wild type (WT) and CYP2E1 knockout
(KO) mice. (e) Histopathology in pyrazole plus TNFα-treated KO (panel a) and WT (panel b). Note: liver injury is decreased in CYP2E1
knockoutmice compared to WT mice.
including nuclear pyknosis, karyorrhexis, and karyolysis
were observed (Figure 2(b)). The treatment with pyrazole
did not signiﬁcantly alter the levels of thiobarbituric acid-
reactive substrates (TBARS) in the total liver extract or the
mitochondria (Figure 2(c)).TNFαtreatment ofcontrol mice
elevated levels of TBARS about 2-3 fold. TBARS in the
homogenates and the mitochondria were further elevated
when TNFα was administered to the pyrazole-treated mice.
Highest liver and mitochondrial TBARs levels were observed
in the pyrazole-plus-TNFα-treated mice (Figure 2(c)). Liver
GSH levels were similar in the saline, pyrazole-treated, and
TNFα-treatedmicebutweredecreasedabout40%intheliver
extracts from the pyrazole-plus-TNFα-treated mice. GSH
levels were lowered 40% in the liver mitochondria from the
pyrazole plus TNFα-treated mice compared to the TNFα
alone treated mice. These results suggest that the combined
pyrazole plus TNFα treatment produces elevated oxidative
stress in the liver compared to TNFαalone or pyrazole alone,
and that mitochondrial oxidativestress may occurin livers of
the pyrazole-plus-TNFα-treated mice.
Asexpected,CYP2E1activityasreﬂectedbytheNADPH-
dependent microsomal oxidation of p-nitrophenol and the
content of CYP2E1 (Western blot analysis) were elevated 2-
to 3-fold by pyrazole or by pyrazole plus TNFα treatment,
over the saline or TNFα alone treated mice. Thus, TNFα
alone or in combination with pyrazole did not alter CYP2E1
activity or content. Also, induction of CYP2E1 alone by
pyrazole is not suﬃcient to induce liver injury; rather, a sec-
ond “hit,” for example, TNFα is required. What is the evi-
dence that induction of CYP2E1 by pyrazole is important for
the elevated injury found in the pyrazole-plus-TNFα-treated
mice? We used CYP2E1 knockout mice to address this ques-
tion. Large increases in ALT and AST levels were found after
TNFα administration to pyrazole-treated SV129 wild typeInternational Journal of Hepatology 7
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Figure 3: Treatment with TNFα plus pyrazole causes mitochondrial injury. TNFα plus pyrazole causes mitochondrial injury as reﬂected
by (a) increased mitochondrial swelling (decreased absorbance at 540nm) or (b) decreased mitochondrial membrane potential as assayed
by succinate-dependent decline in rhodamine 123 ﬂuorescence. The decline in ﬂuorescence after addition of succinate is reﬂective of the
mitochondrial membrane potential. Note: this decline is very small in the mitochondria isolated from TNFα plus pyrazole-treated mice.
In (a) the increased swelling produced by TNFα plus pyrazole is prevented by cyclosporine A (CsA), an inhibitor of the mitochondrial
permeability transition.
mice.TNFαtreatment ofpyrazole-treated CYP2E1knockout
mice did not elevate transaminase levels (Figure 2(d)).
Similarly, TBARs levels in liver homogenates and isolated
mitochondria were not elevated in the TNFα plus pyrazole-
treated CYP2E1 knockout mice but were increased in the
wild-type mice. Normal liver pathology was observed after
pyrazole plus TNFα treatment of CYP2E1 knockout mice.
(Figure 2(e)). The failure of TNFα to induce liver injury in
pyrazole-treated CYP2E1 knockout mice supports a critical
role for CYP2E1 in the potentiated injury observed in the
wild-type mice.
7.Mitochondrial Dysfunction
Alcohol can cause mitochondrial dysfunction [75, 76]. We
hypothesized that mitochondria are an eventual target for
developing liver injury induced by TNFα when CYP2E1 is
elevated by pyrazole. Initiation of a mitochondrial perme-
ability transition was determined by assessing mitochondrial
swelling inthe absenceandpresence of100μMcalcium.Suc-
cinate (10mM) was the respiratory substrate. As shown in
Figure 3(a), in the absence of calcium, swelling (decrease in
absorbanceat540nm)waslowwithallmitochondrialprepa-
rations although there was some basal swelling with the
mitochondria from the pyrazole plus TNFα-treated mice.
The addition of100μM calciumcaused a low rate of swelling
in the saline or TNFα alone mitochondria; swelling was
somewhat elevated in the pyrazole alone mitochondria.
Swelling was very rapid without any lag phase with the
mitochondria from the pyrazole-plus-TNFα-treated mice
(Figure 3(a)). Importantly, this rapid swelling was blocked
by cyclosporine A (2μM), a classic inhibitor of the mito-
chondrial permeability transition. Calcium elevates mito-
chondrial swelling in the saline-, TNFα alone-, and pyrazole
alone groups, which was most pronounced in the TNFα plus
pyrazole group. The calcium-induced swelling was sensitive
to cyclosporine A in all groups. The basal swelling, in the
absence of added calcium, was also higher in the TNFα
pluspyrazole group,furthersuggestiveofmitochondrial dys-
function.
Theelectrochemicalpotentialoftheprotongradientgen-
erated across the mitochondrial membrane (ΔΨ) was as-
sessed by monitoring ﬂuorescence quenching of rhodamine
123. Addition of 10mM succinate at one minute caused
a decrease in ﬂuorescence reﬂective of a high ΔΨ corre-
sponding to state 4 of respiration (Figure 3(b)). The decline
in ﬂuorescence averaged about 40 arbitrary units per minute
with mitochondria from the saline or TNFα alone treated
mice and 30 arbitrary units per minute with mitochondria
fromthepyrazole-treated mice.However,thedeclinein ﬂuo-
rescence was only about 14 arbitrary units with mitochon-
dria from the TNFα-plus-pyrazole-treated mice. Addition of
ADP at 3 minutes caused an enhancement of ﬂuorescence
which corresponds tostate 3 respiration aspart oftheproton8 International Journal of Hepatology
motive force is utilized to synthesize ATP. This enhancement
of ﬂuorescence averaged 15, 14, 12, and 4 arbitrary units
per minute for mitochondria from the saline, TNFα alone,
pyrazole alone,andTNFαpluspyrazole treatedmice,respec-
tively. Taken as a whole, these initial data suggest a small
decline in ΔΨ in mitochondria from the pyrazole-treated
mice and a more pronounced decline in mitochondria from
the pyrazole-plus-TNFα-treated mice.
8.CyclosporineA(CsA)PreventsPyrazole
PlusLPS-InducedLiverInjury[77]
We evaluated whether cyclosporine A (CsA), an inhibitor
of the mitochondrial permeability transition, could protect
against the TNFα-plus-pyrazole-induced liver injury. Such
anexperimentcouldvalidatethatmitochondrialdysfunction
is a key downstream target in this injury. Male C57BL/6mice
were treated with saline, pyrazole, LPS, or pyrazole plus
LPS plus corn oil or pyrazole plus LPS plus 1 dose of CsA
(100mg/kg body wt, dissolved in corn oil). Serum ALT and
AST levels were elevated in the PY + LPS + corn oil group
compared to the other 3 groups. CsA treatment attenuated
this increase in transaminases. H&E staining of liver tissue
showed that the PY + LPS + corn oil treatment induced
extensiveliverzonal necrosis andthattheCsAtreatment pre-
vented this. Mitochondrial swelling was increased in mito-
chondria isolated from the PY + LPS + corn oil treated mice
compared to mitochondria from the saline + corn oil mice.
The in vivo treatment with CsA prevented this increase in
mitochondrial swelling, which likely explains the protection
against LPS-plus-pyrazole-induced liver injury. The LPS
plus pyrazole elevation of 4-HNE and 3-NT protein adducts
were also decreased by CsA, suggesting that mitochondrial
dysfunction plays an important role in the increase in
oxidative/nitrosative stress.
9.ActivationofMAPKinases
Mitogen-activated protein kinases (MAPKs) are serine-thre-
onine kinases that mediate intracellular signaling associated
withavarietyofcellularactivitiesincludingcellproliferation,
diﬀerentiation, survival, death, and transformation. The
mammalian MAPK family consists of extracellular signal-
regulated kinase (ERK), p38 MAPK, and c-Jun NH2-termi-
nal kinase (JNK; also known as stress-activated protein kin-
ase or SAPK) [78]. The MAPK signaling cascade consists
of three distinct members of the protein kinase family, in-
cluding MAP kinase (MAPK), MAPK kinase (MAPKK), and
MAPKK kinase (MAPKKK). MAPKKK phosphorylates and
therebyactivatesMAPKK,andtheactivatedformofMAPKK
in turn phosphorylates and activates MAPK. Activated
MAPK may translocate to the cell nucleus and regulate the
activities of transcription factors and thereby control gene
expression [79, 80]. In either in vivo or in vitro models
of alcoholic liver disease, an increase of gene expression of
the MAPK pathway was found [81, 82]. Compatible data in
protein expression levels were seen in many studies. Intra-
peritoneal injection of alcohol to rats induced rapid phos-
phorylationofp38MAPK,andJNKafteronly1hrofethanol
injection, and this was accompanied with apoptosis of the
liver [83]. In human stellate cells, increased phosphorylation
of p38 MAPK and JNK was found to be associated with
ethanol-induced stellate cell activation, toxicity, and apop-
tosis [84] .J N Ka n dp 3 8M A P Km a yb e c o m ea c t i v a t e ds i m u l -
taneously, while some studies have shown that JNK and p38
M A P Km a ye v e nr e a c ti nt h eo p p o s i t ew a ya c c o r d i n gt ot h e
speciﬁc treatments. In one study, after chronic alcohol feed-
ing, LPS stimulation of Kupﬀer cells increased p38 MAPK
activity, whereas it decreased JNK activity [85]. In human
monocytes, acutealcoholexposure increased JNK phosphor-
ylation, while chronic alcohol exposure decreased JNK ac-
tivity [86]. Apparently, further studies are needed to clarify
why MAPK can react diﬀerently depending on the stimuli or
in diﬀerent cell lines.
MAP kinases such as JNK or p38 MAPK have been
shown to play important roles in several models of liver
injury, including CYP2E1-dependent toxicity [69, 70, 87–
92]. We evaluated possible activation of MAP kinases in
our pyrazole/LPS or pyrazole/TNFα hepatotoxicity models
by assaying for the phosphorylated MAPK. As shown in
Figure 4(a), LPS treatment alone did not cause signiﬁcant
JNK activation or p38 MAPK activation as reﬂected by the
low p-JNK and pp38 MAPK levels relative to total JNK
and p38 MAPK levels. Similar low ratios were found for
the saline or the pyrazole alone treated mice (Figure 4(a)).
H o w e v e r ,b o t hJ N Ka n dp 3 8M A P Kw e r ea c t i v a t e di nl i v e r s
of the pyrazole plusLPS-treated mice. A similar activation of
JNK and p38 MAPK was observed after pyrazole plus TNFα
but not in mice treated with TNFα or pyrazole alone [73].
ERK was not altered by TNFα alone or pyrazole plus TNFα
treatment. To evaluate the signiﬁcance of these changes in
MAPK activation, the eﬀect of SP600125, an inhibitor of
JNK,andSB203580,aninhibitorofp38MAPK,onthehepat-
otoxicity was determined. The TNFα plus pyrazole elevation
oftransaminases was bluntedbyadministration ofSP600125
(15mg/kg) or SB203580 (15mg/kg) (Figure 4(b)). The
MAPK inhibitors also lowered the necrosis (Figure 4(c))
and partially blockedthe increased oxidative stress produced
by the pyrazole plus TNFα treatment, but had no eﬀect on
CYP2E1 activity or protein levels. These results suggest the
CYP2E1 elevation of TNFα liver injury and oxidative stress
is MAPK dependent. The activation of JNK in the pyra-
zole plus TNFα group was blocked by SP600125 but not
SB203580 whereas the activation of p38 MAPK was blocked
by SB203580 but not SP600125.
10.ActivationofASK-1andDownstream
Map KinaseKinases
The upstream mediators of JNK and p38 MAPK activation
were notidentiﬁedin thesepreviousstudies.Formechanistic
and therapeutic implications, it would be important to
evaluate the MAP kinase kinase kinase and MAP kinase
kinase which activate JNK and p38 MAPK in this PY plus
TNFαmodel.Apoptosissignal-regulatingkinase1(ASK-1)is
amember oftheMAP3K familywhich isresponsive tostress-
induced cell damage. Activation of ASK-1 can determine
cell fate by regulation of both the MKK4/MKK7-JNK andInternational Journal of Hepatology 9
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Figure 4: MAP kinase activation. (a) LPS plus pyrazole treatment activates JNK and p38 MAPK. The pJNK/JNK and the pp38
MAPK/p38MAPK ratios are shown below the blots. (b) Either the JNK inhibitor SP600125 (SP) or the p38 MAPK inhibitor SB203508
(SB) prevents TNFα plus pyrazole-induced elevation of ALT and AST or (c) liver pathology.
the MKK3/MKK6-p38 MAPK signaling cascades [93]. ASK-
1 is activated by oxidative stress, ER stress, and inﬂammatory
cytokines such as TNFα [94]. In resting cells, ASK-1 forms
an inactive complex with reduced thioredoxin (Trx). Under
conditionsof stress byTNFαorROS,ASK-1dissociates from
Trx and becomes activated [95]( Figure 5). Oxidation of Trx
by ROS causes dissociation of ASK-1 from the oxidized Trx
which switches the inactive form of ASK-1 to the active
kinase.TheTrx-ASKcomplexisthoughttobearedoxsensor,
which functions as a molecular switch turning the cellular
redox state into a MAP kinase signaling pathway [96]. Ac-
tivated ASK-1 then promotes activation (phosphorylation)
of the downstream MAPKK, MKK4/MKK7 which can ac-
tivate JNK, and MKK3/MKK6which can activate p38 MAPK
[93–96]( Figure 5). We evaluated whether CYP2E1 plus-
TNFα-induced ROS promote release of ASK-1 from the Trx-
ASK1 complex and activate ASK-1 followed by the phos-
phorylation of MKK4/MKK7 and/or MKK3/MKK6 which
subsequently regulate the phosphorylation of JNK and p38
MAPK and contribute to the liver injury.
W i l d - t y p em i c et r e a t e dw i t hP Yp l u sT N F α developed
liver injury between 8 and 12h after TNFα administration as
reﬂected by the high levelsof ALT and ASTat 12h. Oxidative
stress is a likely key factor to trigger signaling and liver injury
in CYP2E1-mediated hepatotoxicity [97]. A time course for
oxidative stress after PY plus TNFα treatment was studied.
GSH was decreased in wild-type mice after 4h and remained
at lower levels for at least 12h as compared to the TNFα
alone group. Lipid peroxidation increased signiﬁcantly at 4h
in the PY-plus-TNFα-treated mice and remained elevated up
to 12h. These results show that oxidative stress occurs at
an earlier time after administration of TNFα than does liver
injury intheTNFα-plus-PY-treated mice.Treatment withPY
increased the levelsofCYP2E1 prior to the administration of
TNFα, and CYP2E1 levels remained about 2-fold elevated at
least until 8h after administration of TNFα in the PY-treated
mice.
Since previous results showed a key role of JNK and
p38 MAPK in the TNFα-plus-PY-induced liver injury, we
evaluated whether upstream MAPKK and MAPKKK were10 International Journal of Hepatology
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Figure 5: Scheme for activation of ASK-1 by ROS/RNS and
downstream MAP kinase kinases (MKK4/7 and MKK 3/6) and
MAP kinase JNK and p38 MAPK by ROS/RNS. Dissociation of
the inhibitory thioredoxin (TRX) from the TRX-ASK-1 complex by
ROS/RNS activates ASK-1. MKPS and MAP kinase phosphatases
which deactivate activated JNK and p38 MAPK by dephosphoryla-
tion are inhibited by ROS/RNS thereby sustaining the activation of
JNK and p38 MAPK.
activated, the time course for their activation in relation to
the hepatic injury, and the role of CYP2E1. We focused on
ASK-1 since this MAPKKK has been shown to be important
as a target for TNFα signaling [93, 94, 96]. TNFα or
pretreatment with PY alone did not activate ASK-1. TNFα
plus PY treatment activated ASK-1 3-fold compared with
the 0 hour control at 4h after TNFα treatment. Activation
of ASK-1 decreased at 8 and 12h. Immunoprecipitation
experiments showed that ASK-1 was bound to Trx-1 at 0h
but was released from the Trx-ASK1 complex at 4h and
remained free from binding to Trx1 at 8 and 12h. No
ASK-1 release from the Trx-ASK1 complex was found in
TNFα alone treated mice. ASK-1 was not activated in PY-
plus-TNFα treated CYP2E1−/− mice, and no ASK-1 was
released from the Trx-ASK1 complex in CYP2E1−/− mice.
Thus, activation of ASK-1 by treatment with TNFα plus PY
is associated with its release from the Trx-ASK1 complex,
occurs prior to the liver injury, and requires CYP2E1.
MKK4/7 and MKK3/6 are the MAPKK which activate
downstream JNK or p38 MAPK, respectively, [98]. They are
also targets for activation by ASK-1 [99, 100]. Treatment of
wild-type mice with PY plus TNFα activated MKK4 at 4,
8, and 12h compared with the TNFα alone groups [101].
No activation of MKK4 was found in TNFα or TNFα +P Y
treated CYP2E1−/− mice [92]. MKK7 was activated only
at 12h. MKK3 was activated as early as 4h in the TNFα-
plus-PY-treated mice, while MKK6 was activated at 8h. JNK
was activated in the TNFα +P Ym i c ea t8a n d1 2 h ,a n d
p38 MAPK was activated at 12h when compared with TNFα
alone. In CYP2E1−/− mice, neither MKK4/7, MKK3/6,
JNK, nor p38 MAPK was activated. Thus, the time course
experiments suggest MKK4 may be the MAPK responsible
for activation of JNK, while either MKK3 or MKK6 may be
the MAPKK responsible for the activation of p38 MAPK.
In summary, a time course of in vivo liver injury induced
by PY plus TNFα was carried out to determine the sequence
of events and relationships between induction of CYP2E1,
oxidative stress, the activation of ASK-1, MKK3/MKK6,
MKK4/MKK7, p38 MAPK and JNK with the development
of liver injury [101]. The liver injury occurs at 8 to 12h after
the additionof TNFα. SinceROS is postulated to be a critical
factor in themechanism by which TNFαplusPY induceliver
injury, development of ROS should precede the liver injury.
Indeed, hepatic GSH levels were decreased and TBARS levels
were elevated 4h after administration of TNFα to PY-treated
mice. Thus oxidative stress precedes the liver injury. A like-
ly contributor to the increase in oxidative stress is the induc-
tion of CYP2E1 by the pyrazole treatment as no injury or
oxidative stress was observed in CYP2E1 knockout mice.
CYP2E1 levels were already elevated at the time of TNFα
administration (0h) since the mice were treated for two days
pri ort oth i si n j ecti onofT NFαon day3.ASK-1,a member of
the MAPKKK family, activates both MKK4/MKK7-JNK and
MKK3/MKK6-p38 MAPK signaling cascades. ASK-1 was
activated in PY-treated mice at 4h after the administration
of TNFα. Immunoprecipitation analysis showed that ASK-
1 was dissociated from the inactive Trx-ASK complex at
4h, consistent with the activation of ASK-1 at 4h. In
CYP2E1−/− mice, pyrazole plus TNFα treatment failed to
activate ASK-1 and ASK-1 was not dissociated from the Trx-
ASK1 complex. If CYP2E1-generated ROS is important for
the release and activation of ASK-1, elevation of CYP2E1
and in oxidative stress should occur as early events. Increases
in CYP2E1 and ROS occur at 4h, at least consistent with
the activation of ASK-1 at 4h, although future experiments
with shorter time intervals will be necessary to evaluate these
relationships in more detail. Our results implicate a role for
ASK-1inCYP2E1potentiationofTNFα-inducedliverinjury.
Future experiments with ASK-1 knockout mice [102] would
be interesting to further validate the role of ASK-1 in the
PY/TNFα model. JNK or p38 MAPK activities are increased
upon phosphorylation by MAPK kinase (MKK4/MKK7
or MKK3/MKK6) [98]. The activity of ASK-1 modulates
and regulates the phosphorylation of MKK4/MKK7 and
MKK3/MKK6. PY plus TNFα treatment increased MKK4
phosphorylation at 4, 8, and 12h, while activation of MKK7
was delayed until 12h. MKK3 and MKK6 phosphorylations
were also increased at 4 to 8h. In CYP2E1−/− mice, no
MAPKK was activated at any observation time point. TNFα
alone did not signiﬁcantly activate the MAPKK in wild-type
or CYP2E1−/− mice. The activation of MKK4 and MKK3/6
(4–8h) occur prior to the onset of liver injury (8–12h).
The role of CYP2E1 in the activation of ASK-1, MKK4/
MKK7 or MKK3/MKK6 is apparent, since TNFα treatment
only induced such activations in wild type mice treated with
PY to induce CYP2E1 but not in CYP2E1−/− mice. We hy-
pothesize that TNFαalone- orCYP2E1 alone-generatedROS
stress is not suﬃcient to trigger the dissociation of ASK-
1 from the Trx-ASK complex. The CYP2E1 sensitization of
TNFα-induced liver injury may occur through a synergistic
eﬀect with TNFα to produce an enhanced ROS stress con-
sistent with the so-called “Two Hit”hypothesis. We speculate
that similar interactions between CYP2E1 and TNFα may be
important for alcohol-induced liver injury.International Journal of Hepatology 11
11.Thioredoxin-CYP2E1-ASK-1-JNK1
Interactions
The thioredoxin system plays a key role in modulating redox
signaling pathways which regulate physiological as well as
pathophysiological processes [103, 104]. The thioredoxin
system includes thioredoxin, thioredoxin reductase, and
thioredoxin peroxidases. Thioredoxin has a conserved cat-
alytic site (-Cys-Gly-Pro-Cys-Lys-) that undergoes reversible
oxidation to the cystine disulﬁde. Oxidized thioredoxin is
a major substrate for thioredoxin reductase, and reduced
thioredoxin serves as an electron carrier to reduce peroxire-
doxins. The oxidized thioredoxin is reduced back to the re-
duced form by thioredoxin reductase [105, 106]. There are
two main thioredoxins: thioredoxin-1 (TRX-1), a cytosolic
form; thioredoxin-2 (TRX-2), a mitochondrial form [105].
Modiﬁcation of thiols in thioredoxin interrupts signaling
mechanisms involvedincellgrowth,proliferation,andapop-
tosis. The role of thioredoxin in the regulation of the ac-
tivation of apoptosis signal-regulating kinase-1 (ASK-1) and
downstream apoptosis pathways has been reported in multi-
ple studies [95, 96, 106, 107]. Thioredoxin can associate with
the N-terminal portion of ASK-1 in vitro and in vivo. Ex-
pression of thioredoxin inhibited ASK-1 kinase activity and
the subsequent ASK-1-dependentapoptosis [107]. In resting
cells, endogenous ASK-1 constitutively forms a complex
which includes thioredoxin. Upon ROS stimulation, the
ASK-1 unbinds from thioredoxin and forms a fully activated
higher-molecular-mass complex. As discussed above, TNFα
increases oxidativestress in mice with elevatedCYP2E1, with
subsequent activation of ASK-1 via a mechanism involving
thioredoxin-ASK-1 dissociation, followed by activation of
downstream MKK and MAPK [101].
Both TRX-1 and TRX-2 are involved in the protection
from oxidative stress. TRX-2 plays an important role in pro-
tecting the mitochondria against oxidative stress and in pro-
tecting cells from ROS-induced apoptosis. Supplementation
of human recombinant TRX-1 to mice fed a Lieber-DeCarli
ethanol diet decreased several markers of oxidative stress,
inﬂammatory cytokine expression, and apoptosis in liver
[108]. Since thioredoxin is a reducing molecule which can
decrease oxidative stress, we evaluated [109] whether thiore-
doxin can inhibit the oxidative stress induced by CYP2E1,
and whether there is any diﬀerence in the function of TRX-
1 versus TRX-2 in blunting CYP2E1 oxidant stress. SiRNA
for either TRX-1 or TRX-2 was added to HepG2 cells with
CYP2E1 expression (E47 cells) or without CYP2E1 expres-
sion (C34 cells) to test (1) whether thioredoxin decreases
oxidative stress and injury induced by CYP2E1; (2)consider-
ing thecompartmentation ofthioredoxin, whetherTRX-1or
TRX-2 has a stronger protective eﬀect in preventing against
this injury and oxidative stress; (3) what the mechanism of
the protection by thioredoxin from cell death in CYP2E1-
expressing cells is [109].
Both E47 and C34 cells were treated with either control
siRNA, TRX-1 siRNA, or TRX-2 siRNA, or both TRX-1 and
TRX-2 siRNA for 72hrs. TRX-1 expression was decreased
by 90% by either TRX-1 siRNA alone or TRX-1 and TRX-
2 siRNA together in both cell lines. TRX-2 expression was
decreased by 80–90% by TRX-2 siRNA alone or TRX-1 and
TRX-2 siRNA together in both cell lines. TRX-1 siRNA is
speciﬁc for cytosolic thioredoxin and had no eﬀect on levels
of mitochondrial thioredoxin, and TRX-2 siRNA is speciﬁc
for decreasing mitochondrial thioredoxin and had no eﬀect
on levels of cytosolic thioredoxin.
Knockdown of TRX-1 or TRX-2 or both decreased cell
viability of E47 cells by 40–60%, but cell viability of C34
cells was not aﬀected with the knockdown of either TRX-1
or TRX-2 or both (Figure 6(a)). These results indicate that
cell death induced by thioredoxin knockdown under these
conditions is CYP2E1 dependent and that decreasing either
TRX-1 or TRX-2 promotes this toxicity. To assess the mode
of cell death, experiments studying uptake of propidium
iodideorannexin Vstaining were carriedout.Uptakeofpro-
pidium iodide into E47 cells was elevated upon knockdown
of eitherTRX-1orTRX-2or both.Annexin Vstaining, taken
as a reﬂection of apoptosis, was also elevated in the E47 cells
upon knockdown of TRX-1 or TRX-2 or both. Thus, the cell
death appears to be a mix of necrosis plus apoptosis, that
is, necroptosis. We next evaluated whether knocking down
of thioredoxin intracellularly by siRNA induces ROS pro-
duction and lipid peroxidation. Total ROS was detected
both by ﬂuorescence microscopy, ﬂow cytometry assay, and
spectroﬂuorimetry assay. An increase of ROS production
was detected in E47 cells but not in C34 cells after 72hrs
treatment with either TRX-1 or TRX-2 siRNA or both.
Quantiﬁcation of ROS production by spectroﬂuorimetry
indicated that total ROS production was elevated 50–100%
by thioredoxin knockdown in E47 cells (Figure 6(b)). There
were no increases in ROS production in C34 cells upon
thioredoxin knockdown. There were signiﬁcant increases of
ROS production when either TRX-1 or TRX-2 was lowered.
This suggests that TRX-1 alone or TRX-2 alone is not suf-
ﬁcient to protect the E47 cells from oxidative stress. It would
appear that both TRX-1 or TRX-2 are essential for the
protection of E47 cells from oxidative stress. The production
of superoxide was assayed using dihydroethidium (DHE) as
theprobe.KnockdownofTRX-1orTRX-2orbothincreased
DHE ﬂuorescence in E47 cells, but not C34 cells. 4-HNE
adduct formation was analyzed by immunocytochemistry
with ﬁxed E47 and C34 cells. At baseline, 4-HNE adduct
expression is higher in E47 cells than C34 cells when control
siRNA was applied, similar to the increase in ﬂuorescence
of E47 compared to C34 cells. There was no increase of
4-HNE adducts in C34 cells, but a signiﬁcant increase of
4-HNE adducts was observed in E47 cells when comparing
either TRX-1 or TRX-2 or both siRNA treatment to control
siRNA treatment. Treatment with either TRX-1 or TRX-2
siRNA or both did not cause a signiﬁcant change of total
glutathione level in C34 cells, while a 50% decrease was
found in E47 cells (Figure 6(c)). This suggests that with
knockdown of thioredoxin, glutathione was consumed as a
major reducing molecule and antioxidant. Addition to the
culture medium of glutathione ethyl ester prevented E47
cell death caused by either TRX-1 or TRX-2 siRNA or both
together (Figure 6(d)). The lowering of, as well as the pro-
tection by, glutathione suggests that the knockdown of thi-
oredoxin-induced cell death is related to oxidative stress.12 International Journal of Hepatology
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Figure 6: Eﬀect of thioredoxin (TRX) knockdown on E47 (express CYP2E1) and C34 (do not express CYP2E1) HepG2 cell viability. E47
and C34cells were treated with control siRNA or cytosolic TRX-1 siRNA ormitochondrial TRX-2 siRNA orboth TRX-1 and TRX-2 siRNAs
for 72 hours. (a) Cell viability was determined by a MTT assay. (b) ROS production was determined by a ﬂuorescence assay. Arbitrary
units of ﬂuorescence by the E47 and C34 cells. (c) Cellular levels of glutathione (GSH). The GSH level in each group was expressed as the
value relative to that of the control siRNA treatment group in E47 cells. (d) Supplementation with GSH restores E47 cell viability after TRX
knockdown. At 24 hours, 5mM glutathione ethyl ester (GSSE) was added to the cell culture medium, and the cells were incubated with the
indicated siRNA for 48 hours followed by MTT assay. Note: both cytosolic and mitochondrial TRX are important in protection of HepG2
cells from CYP2E1-generated oxidant stress.
Since thioredoxin is bound to ASK-1 and inhibits the
activationofASK-1,experimentswerecarriedouttoevaluate
whether thioredoxin knockdownactivates ASK-1and down-
stream MAPK signaling pathways in the E47 cells. Increased
ASK-1 phosphorylation was seen by immunohistochemistry
i nE 4 7c e l l su p o nt r e a t m e n tw i t hT R X - 1o rT R X - 2s i R N A
or both at 5, 24, and 48hrs, but not after 72hrs of
siRNA treatment. Western blot analysis revealed a 2–4-fold
increase in the pASK-1/ASK-1 ratio 24hrs and 48hrs but
not after 72hrs of thioredoxin knockdown. ASK-1 activates
downstream MAPK such as JNK and p38 MAPK, ultimately
bypromotingtheirphosphorylation topJNKorpp38MAPK
[95, 96]. Increased JNK1 but not JNK2 phosphorylation was
seen in E47 cells treated with either TRX-1 or TRX-2 siRNA
for 48hrs (Figure 7(b)). No such activation persisted at 72
hrs after treatment. Thus, activation of JNK1 occurs after
the earlier activation of ASK-1 (5–48hrs) and declines when
activation of ASK-1 terminates (72hrs). p38 MAPK was not
activated under these conditions as there was no increase in
pp38 MAPK levels. One downstream target of JNK1 is cJUN
phosphorylation. There was an increase in the pc-JUN/c-
JUN ratio 72hrs after treatment with siRNA for TRX-1,
TRX-2, or both, a time point after the activation of JNK1
(48hrs).International Journal of Hepatology 13
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Figure 7: A JNK inhibitor protects the E47 cells from loss of viability produced by TRX knockdown. The E 47 cells were incubated with
and without 5uM of the JNK inhibitor L-JNKI1for 3 hours followed by treatment with the indicated siRNA for 48 or 72 hours. (a) MTT
assayto determine cell viability. (b) The eﬀect ofTRX knockdownonthe activationofJNK inthe absence and presence ofthe JNKinhibitor.
Numbers under the blots refer to the pJNK/JNK ratio.
Could theCYP2E1 plusthioredoxinknockdowninduced
cell death be mediated through ASK-1 and JNK1 signaling
pathways? The JNK inhibitor, L-JNKI1, which speciﬁcally
inhibits the phosphorylation of JNK, lowered the decline
in E47 cell viability from 45–50% in the absence of L-
JNKI1 to about 20–30% in the presence of L-JNKI1 plus
TRX-1, or TRX-2 siRNA, or both TRX-1 and TRX-2 siRNA
treatment (Figure 7(a)). Under these conditions, L-JNKI1
strongly blunted the activation of JNK which occurs 48hrs
after thioredoxin knockdown; the pJNK1/JNK1 ratio was
elevated 2- to 4-fold by siRNA for TRX-1 or TRX-2 or both
intheabsence ofJNKI1,whereas no increase inpJNK1/JNK1
was observed in the presence of the inhibitor (Figure 7(b)).
The partial protection by L-JNKI1 suggests that the cell
deathinducedbythioredoxinknockdownwaspartlyvia JNK
signaling pathways, although non-JNK-dependent pathways
are also likely involved.
In conclusion, both cytosolic and mitochondrial thiore-
doxin are important in protecting HepG2 cells from cell
death by oxidative stress induced by CYP2E1. Thioredox-
in knockdown increased cellular production of ROS and
increased lipid peroxidation in HepG2 cells expressing
CYP2E1. The signaling pathway which induced cell death
by thioredoxin knockdown may involve, at least in part, the
activationofASK-1andJNK1.ThisprotectionbybothTRX-
1a n dT R X - 2a g a i n s tC Y P 2 E 1 - d e p e n d e n tt o x i c i t ym a yp l a ya
role in the ability of thioredoxin to protect against ethanol-
induced hepatotoxicity [108] and suggests that antioxidative
protection in both the cytosol and mitochondria is necessary
for eﬀective protection against liver injury potentiated by
CYP2E1.
12.EffectofN-Acetylcysteine (NAC)
We evaluated [74]t h ee ﬀect of NAC, a general antioxidant
andaprecursorofGSH,onthepotentiationofTNFαtoxicity
by pyrazole as a proof of principle that oxidative stress plays
an important role in the overall liver injury. C57BL/6 mice
were treated with pyrazole for two days and then challenged
with either saline or TNFα. Some mice in each group were14 International Journal of Hepatology
0
200
400
600
800
1000
1200
1400
1600
Saline PY TNFα TNFα +P Y
A
L
T
(
u
n
i
t
s
/
L
)
∗
(a)
Saline PY TNFα TNFα +P Y
∗
0
100
200
300
400
500
600
700
800
900
A
S
T
(
u
n
i
t
s
/
L
)
(b)
Saline PY TNFα TNFα +P Y
∗
T
B
A
R
S
(
n
m
o
l
e
s
/
m
g
)
3.5
3
2.5
2
1.5
1
0.5
0
B6-129PF2/J
NOS2−/−
(c)
Saline PY TNFα TNFα +P Y
∗
G
S
H
(
n
m
o
l
e
s
/
m
g
)
0
10
20
30
40
50
60
B6-129PF2/J
NOS2−/−
(d)
Figure 8: TNFα-plus-pyrazole-induced hepatotoxicity and oxidative stress are decreased in iNOS knockout mice. B6-129 WT mice and
B6-129 iNOS knockoutmice (NOS2−/−) were treated with either saline or pyrazole alone or TNFα alone or pyrazole plus TNFα for 3 days
followed by assays of (a) ALT/AST, (b) TBARS, and (c) GSH. Note: liver injury and oxidant stress were much lower in the NOS2−/− mice
than the WT mice indicating a role for NO and NO metabolites in the TNFα-plus-pyrazole-induced liver injury and oxidative stress.
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Figure 9: Model for the potentiation of TNFα-induced hepatotoxicity, oxidative stress mitochondrial dysfunction, and activation of MAPK
bypyrazole inductionofCYP2E1.PyrazoleinductionofCYP2E1coupledtoTNFαinductionofiNOSresultsinelevatedoxidative/nitrosative
stress in hepatocytes. This results in activation of JNK and p38 MAPK which, along with the elevated ROS/RNS, damage mitochondrial
function ultimately leading to liver injury.
also treated with 150mg/kg NAC on the second day of
treatment with pyrazole and on day 3 prior to the challenge
with TNFα. The elevation in ALT and AST and the necrosis
caused by the pyrazole plus TNFα treatment were lowered
by NAC. The increase in TBARs produced by pyrazole plus
TNFα and the decline in liver GSH were both prevented
by NAC. Treatment with NAC had no eﬀect on CYP2E1
protein levels or CYP2E1 catalytic activity. The activation of
JNK or p38 MAPK by the pyrazole plus TNFα treatment,
compared to pyrazole alone, was blocked by NAC. TheInternational Journal of Hepatology 15
pyrazole plus TNFα treatment elevated levels of iNOS 2.6-
fold, and this increase in iNOS was blunted by NAC to a 1.4-
fold increase. These results with NAC suggest that elevated
oxidative stress is central to the activation of JNK and p38
M A P K ,t op e r o x y n i t r i t ef o r m a t i o n ,a n dt ot h el i v e ri n j u r y
produced by treatment with pyrazole plus TNFα.
13.Pyrazole/TNFα Hepatotoxicity in
iNOS KnockoutMice
The inducible nitric oxide synthase (iNOS) has been shown
to play an important role in alcohol-induced liver injury
[110]. We hypothesized that induction of CYP2E1 by pyra-
zole and induction of iNOS by LPS/TNFα result in the for-
mation of the powerful oxidant peroxynitrite, ONOO, de-
rived from the reaction between O2
−￿ and NO. 3-Nitroty-
rosine proteinadducts (3-NT) were elevated in the liver after
pyrazole plusLPS treatment [71, 72].We believethat ONOO
playsakeyrole intheoxidative/nitrosative stress and hepato-
toxicity produced by the pyrazole plus LPS/TNFα treatment.
Ifcorrect,oxidative/nitrosativestress andhepatotoxicitypro-
duced by pyrazole plus LPS/TNFα treatment should be
blunted in iNOS null mice. NOS2 (iNOS) knockout mice
(B6-129P2) and genetic background control B6-129PF2/J
mice were purchased from Jackson Laboratory and treated
with saline or pyrazole alone or TNFα alone or pyrazole
plus TNFα. The pyrazole plus TNFα treatment elevated ALT
or AST levels about 2-fold (P<0.05) in iNOS null mice
as compared to treatment with saline or pyrazole alone or
TNFα alone (Figure 8(a)). Pyrazole plus TNFα elevated ALT
and AST about four- to ﬁvefold in the genetic background
mice (Figure 8(a))( P<. 01 compared to the increase in
ALT and AST in iNOS null mice). In NOS2−/− mice, TNFα
plus PY induced some hepatocyte degeneration change in
the pericentral area but no loci of necrosis were found. In
the control wild-type B6-129PF2/J mice, TNFα plus PY in-
duced more severe liver injury and necrotic loci were found
in several pericentral areas. TNFα plus PY slightly in-
creased lipid peroxidation in NOS2−/− mice compared with
saline-, PY-, or TNFα-treated mice. Lipid peroxidation was
more signiﬁcantly elevated by TNFα-plus-PY treatment in
B6-129PF2/J mice (4-fold increase) compared to the other
groups and to the TNFα plus PY treated NOS2−/− mice
(2-fold increase, Figure 8(b)). TNFα plus PY lowered GSH
levels by 25% in NOS2−/− mice, while a more pronounced
decline in GSH occurred in the control mice (67% decrease,
Figure 8(c)). Levels of CYP2E1 were elevated to comparable
extents by pyrazole in the wild-type and the iNOS knockout
mice (about 2.5–3-fold); thus, the lower liver injury in the
iNOS knockout mice is not due to lower levels of CYP2E1.
These results suggest that while TNFα plus PY does induce
some liver injury and oxidant stress in the NOS2−/− mice,
a more severe liver injury and oxidant stress is induced
by TNFα plus PY in the control mice. We hypothesize
that NO derived from iNOS reacts with superoxide radical
produced from CYP2E1 to generate the powerful oxidant
peroxynitrite which plays a critical role in the liver injury
produced by TNF plus pyrazole. The absence of iNOS in the
knockout mice with the accompanying decline in NO would
prevent formation of signiﬁcant amounts of peroxynitrite
even though superoxide continues to be produced from the
elevated CYP2E1 and therefore liver injury is lowered.
14.Conclusions
This paper has focused on two major contributors to mech-
anisms by which ethanol causes liver injury, induction of
CYP2E1, and elevated endotoxin(LPS) levelsfollowed by in-
creased production of TNFα. Each of these has been ex-
tensively studied, but there are few studies in which both
factors have been evaluated simultaneously. We have shown
that induction of CYP2E1 by pyrazole potentiates LPS- or
TNF-induced hepatotoxicity. Evidence for a role for CYP2E1
comes from studies in which the CYP2E1 inhibitor CMZ
blockstheliverinjury,and fromstudieswithCYP2E1knock-
out mice where pyrazole plus LPS toxicity is blunted. The
potentiatedtoxicityisassociatedwithanincreaseinoxidative
and nitrosative stress. Prevention of such increases, for ex-
ample, treatment with the antioxidant NAC or administra-
tion of TNFα plus pyrazole to iNOS knockout mice, blunts
the liver injury thus validating that the elevated oxidative/
nitrosative stress plays a key role in producing the liver in-
jury rather than occurs because of liver injury. JNK and
P38 MAP kinases are activated by the combined pyrazole
plusLPS/TNFαtreatment. PreventingactivationofJNKwith
SP600125 or activation of P38 MAPK with SB203580 de-
creases the liver injury. Inhibition of CYP2E1 or use of
CYP2E1 knockout or iNOS knockout mice or preventing
the oxidative/nitrosative stress decreases the activation of
JNK and P38 MAPK. We hypothesize that the increase in
oxidative/nitrosativestressandtheactivationofMAPkinases
ultimatelyimpactonmitochondrial integrityandfunctionas
shown by the increase in mitochondrial swelling and decline
in mitochondrial membrane potential. Protection of mito-
chondrial integrity with cyclosporine A prevents the TNFα-
plus-pyrazole-induced hepatotoxicityandoxidativestress. In
HepG2 cells expressing CYP2E1, both cytosolic and mito-
chondrial TRX are necessary for protection against CYP2E1-
generated oxidative stress, and cell toxicity. We hypothesize
thatsimilarinteractionsinvolvingactivationofMAPkinases,
oxidative stress and mitochondrial dysfunction occur as a
result of ethanol induction of CYP2E1 and elevation of
LPS/TNFα, and our working scheme is shown in Figure 9.
Induction ofCYP2E1 by pyrazole orethanol increases super-
oxide radical production, while elevation of LPS/TNFα by
ethanol activates iNOS and NO production. The interaction
between superoxide and NO produces the powerful oxidant
peroxynitrite. Downstream targets for ROS and RNS include
activation of ASK-1 and subsequently JNK and mitochon-
drial dysfunction which contribute to loss of viability.
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